1dn2 › Citations

Convergent solutions to binding at a protein-protein interface.

DeLano WL, Ultsch MH, de Vos AM, Wells JA
Science 287 1279-83 (2000)
Cited: 385 times
EuropePMC logo PMID: 10678837

Abstract

The hinge region on the Fc fragment of human immunoglobulin G interacts with at least four different natural protein scaffolds that bind at a common site between the C(H2) and C(H3) domains. This "consensus" site was also dominant for binding of random peptides selected in vitro for high affinity (dissociation constant, about 25 nanomolar) by bacteriophage display. Thus, this site appears to be preferred owing to its intrinsic physiochemical properties, and not for biological function alone. A 2.7 angstrom crystal structure of a selected 13-amino acid peptide in complex with Fc demonstrated that the peptide adopts a compact structure radically different from that of the other Fc binding proteins. Nevertheless, the specific Fc binding interactions of the peptide strongly mimic those of the other proteins. Juxtaposition of the available Fc-complex crystal structures showed that the convergent binding surface is highly accessible, adaptive, and hydrophobic and contains relatively few sites for polar interactions. These are all properties that may promote cross-reactive binding, which is common to protein-protein interactions and especially hormone-receptor complexes.

Reviews - 1dn2 mentioned but not cited (5)

  1. Neonatal Fc receptor and IgG-based therapeutics. Kuo TT, Aveson VG. MAbs 3 422-430 (2011)
  2. Function and 3D structure of the N-glycans on glycoproteins. Nagae M, Yamaguchi Y. Int J Mol Sci 13 8398-8429 (2012)
  3. Fc-Binding Ligands of Immunoglobulin G: An Overview of High Affinity Proteins and Peptides. Choe W, Durgannavar TA, Chung SJ. Materials (Basel) 9 E994 (2016)
  4. Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology. Robinson JA. J Pept Sci 19 127-140 (2013)
  5. Affinity-Based Methods for Site-Specific Conjugation of Antibodies. von Witting E, Hober S, Kanje S. Bioconjug Chem 32 1515-1524 (2021)

Articles - 1dn2 mentioned but not cited (25)



Reviews citing this publication (84)

  1. Fcgamma receptors as regulators of immune responses. Nimmerjahn F, Ravetch JV. Nat Rev Immunol 8 34-47 (2008)
  2. FcRn: the neonatal Fc receptor comes of age. Roopenian DC, Akilesh S. Nat Rev Immunol 7 715-725 (2007)
  3. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Wells JA, McClendon CL. Nature 450 1001-1009 (2007)
  4. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Arkin MR, Wells JA. Nat Rev Drug Discov 3 301-317 (2004)
  5. Principles of docking: An overview of search algorithms and a guide to scoring functions. Halperin I, Ma B, Wolfson H, Nussinov R. Proteins 47 409-443 (2002)
  6. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Arkin MR, Tang Y, Wells JA. Chem Biol 21 1102-1114 (2014)
  7. Is allostery an intrinsic property of all dynamic proteins? Gunasekaran K, Ma B, Nussinov R. Proteins 57 433-443 (2004)
  8. Hot spots--a review of the protein-protein interface determinant amino-acid residues. Moreira IS, Fernandes PA, Ramos MJ. Proteins 68 803-812 (2007)
  9. Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes. Pelay-Gimeno M, Glas A, Koch O, Grossmann TN. Angew Chem Int Ed Engl 54 8896-8927 (2015)
  10. Multiple diverse ligands binding at a single protein site: a matter of pre-existing populations. Ma B, Shatsky M, Wolfson HJ, Nussinov R. Protein Sci 11 184-197 (2002)
  11. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Hogarth PM, Pietersz GA. Nat Rev Drug Discov 11 311-331 (2012)
  12. Human antibody-Fc receptor interactions illuminated by crystal structures. Woof JM, Burton DR. Nat Rev Immunol 4 89-99 (2004)
  13. The molecular basis of TCR germline bias for MHC is surprisingly simple. Garcia KC, Adams JJ, Feng D, Ely LK. Nat Immunol 10 143-147 (2009)
  14. Oncogenic protein interfaces: small molecules, big challenges. Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW. Nat Rev Cancer 14 248-262 (2014)
  15. Phage display in pharmaceutical biotechnology. Sidhu SS. Curr Opin Biotechnol 11 610-616 (2000)
  16. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Smith MC, Gestwicki JE. Expert Rev Mol Med 14 e16 (2012)
  17. Antagonists of protein-protein interactions. Cochran AG. Chem Biol 7 R85-94 (2000)
  18. Cell-division inhibitors: new insights for future antibiotics. Lock RL, Harry EJ. Nat Rev Drug Discov 7 324-338 (2008)
  19. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Sockolosky JT, Szoka FC. Adv Drug Deliv Rev 91 109-124 (2015)
  20. Phage display: selecting straws instead of a needle from a haystack. Vodnik M, Zager U, Strukelj B, Lunder M. Molecules 16 790-817 (2011)
  21. Human IgG4: a structural perspective. Davies AM, Sutton BJ. Immunol Rev 268 139-159 (2015)
  22. Exploring protein-protein interactions with phage display. Sidhu SS, Fairbrother WJ, Deshayes K. Chembiochem 4 14-25 (2003)
  23. The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies. Menendez A, Scott JK. Anal Biochem 336 145-157 (2005)
  24. Rheumatoid factors: host resistance or autoimmunity? Newkirk MM. Clin Immunol 104 1-13 (2002)
  25. Recognition of immunoglobulins by Fcgamma receptors. Radaev S, Sun P. Mol Immunol 38 1073-1083 (2002)
  26. Hsp70 protein complexes as drug targets. Assimon VA, Gillies AT, Rauch JN, Gestwicki JE. Curr Pharm Des 19 404-417 (2013)
  27. Membrane-bound diiron carboxylate proteins. Berthold DA, Stenmark P. Annu Rev Plant Biol 54 497-517 (2003)
  28. Protein functional epitopes: hot spots, dynamics and combinatorial libraries. Ma B, Wolfson HJ, Nussinov R. Curr Opin Struct Biol 11 364-369 (2001)
  29. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. Sheng C, Dong G, Miao Z, Zhang W, Wang W. Chem Soc Rev 44 8238-8259 (2015)
  30. The design, structures and therapeutic potential of protein epitope mimetics. Robinson JA, Demarco S, Gombert F, Moehle K, Obrecht D. Drug Discov Today 13 944-951 (2008)
  31. Macrocycles as protein-protein interaction inhibitors. Dougherty PG, Qian Z, Pei D. Biochem J 474 1109-1125 (2017)
  32. Disruption of protein-protein interactions: towards new targets for chemotherapy. Loregian A, Palù G. J Cell Physiol 204 750-762 (2005)
  33. Mechanistic diversity of cytokine receptor signaling across cell membranes. Stroud RM, Wells JA. Sci STKE 2004 re7 (2004)
  34. Computational prediction of protein hot spot residues. Morrow JK, Zhang S. Curr Pharm Des 18 1255-1265 (2012)
  35. LG/LNS domains: multiple functions -- one business end? Rudenko G, Hohenester E, Muller YA. Trends Biochem Sci 26 363-368 (2001)
  36. The many faces of Ras: recognition of small GTP-binding proteins. Corbett KD, Alber T. Trends Biochem Sci 26 710-716 (2001)
  37. Complexity and simplicity of ligand-macromolecule interactions: the energy landscape perspective. Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Freer ST, Rose PW. Curr Opin Struct Biol 12 197-203 (2002)
  38. Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics. Zorzi A, Linciano S, Angelini A. Medchemcomm 10 1068-1081 (2019)
  39. TRIM21 and the Function of Antibodies inside Cells. Rhodes DA, Isenberg DA. Trends Immunol 38 916-926 (2017)
  40. News from the protein mutability landscape. Hecht M, Bromberg Y, Rost B. J Mol Biol 425 3937-3948 (2013)
  41. Exploring privileged structures: the combinatorial synthesis of cyclic peptides. Horton DA, Bourne GT, Smythe ML. Mol Divers 5 289-304 (2002)
  42. Luxury accommodations: the expanding role of structural plasticity in protein-protein interactions. Sundberg EJ, Mariuzza RA. Structure 8 R137-42 (2000)
  43. Antibody Aggregation: Insights from Sequence and Structure. Li W, Prabakaran P, Chen W, Zhu Z, Feng Y, Dimitrov DS. Antibodies (Basel) 5 E19 (2016)
  44. Exploring privileged structures: the combinatorial synthesis of cyclic peptides. Horton DA, Bourne GT, Smythe ML. J Comput Aided Mol Des 16 415-430 (2002)
  45. Piecing together the family portrait of TCR-CD3 complexes. Kuhns MS, Badgandi HB. Immunol Rev 250 120-143 (2012)
  46. Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery. Hall DR, Kozakov D, Whitty A, Vajda S. Trends Pharmacol Sci 36 724-736 (2015)
  47. Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery. Hallenbeck KK, Turner DM, Renslo AR, Arkin MR. Curr Top Med Chem 17 4-15 (2017)
  48. The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics. Cox R, Plemper RK. Front Microbiol 6 459 (2015)
  49. Multiple paths to multispecificity. Mariuzza RA. Immunity 24 359-361 (2006)
  50. G protein betagamma subunits as targets for small molecule therapeutic development. Smrcka AV, Lehmann DM, Dessal AL. Comb Chem High Throughput Screen 11 382-395 (2008)
  51. Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies. Le NP, Bowden TA, Struwe WB, Crispin M. Biochim Biophys Acta 1860 1655-1668 (2016)
  52. Peptide interactions with G-protein coupled receptors. Marshall GR. Biopolymers 60 246-277 (2001)
  53. Synthetic cell surface receptors for delivery of therapeutics and probes. Hymel D, Peterson BR. Adv Drug Deliv Rev 64 797-810 (2012)
  54. New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics. Smith AJ. J Biomol Screen 20 437-453 (2015)
  55. Affinity chromatography: A versatile technique for antibody purification. Arora S, Saxena V, Ayyar BV. Methods 116 84-94 (2017)
  56. One from column A and two from column B: the benefits of phage display in molecular-recognition studies. Rodi DJ, Makowski L, Kay BK. Curr Opin Chem Biol 6 92-96 (2002)
  57. In silico Approaches for the Design and Optimization of Interfering Peptides Against Protein-Protein Interactions. Hashemi ZS, Zarei M, Fath MK, Ganji M, Farahani MS, Afsharnouri F, Pourzardosht N, Khalesi B, Jahangiri A, Rahbar MR, Khalili S. Front Mol Biosci 8 669431 (2021)
  58. Multiple ligand binding sites on domain seven of human complement factor H. Giannakis E, Male DA, Ormsby RJ, Mold C, Jokiranta TS, Ranganathan S, Gordon DL. Int Immunopharmacol 1 433-443 (2001)
  59. Survey of the year 2000 commercial optical biosensor literature. Rich RL, Myszka DG. J Mol Recognit 14 273-294 (2001)
  60. Protein interaction networks as starting points to identify novel antimicrobial drug targets. Zoraghi R, Reiner NE. Curr Opin Microbiol 16 566-572 (2013)
  61. Interactions between immunoglobulin G molecules. Nezlin R. Immunol Lett 132 1-5 (2010)
  62. Structural insights into the interactions between human IgE and its high affinity receptor FcepsilonRI. Wurzburg BA, Jardetzky TS. Mol Immunol 38 1063-1072 (2002)
  63. G-protein-directed ligand discovery with peptide combinatorial libraries. Ja WW, Roberts RW. Trends Biochem Sci 30 318-324 (2005)
  64. Precision Modification of Native Antibodies. Wu KL, Yu C, Lee C, Zuo C, Ball ZT, Xiao H. Bioconjug Chem 32 1947-1959 (2021)
  65. Protein therapeutics: promises and challenges for the 21st century. Weng Z, DeLisi C. Trends Biotechnol 20 29-35 (2002)
  66. Engineered protein scaffolds as leads for synthetic inhibitors of protein-protein interactions. Wuo MG, Arora PS. Curr Opin Chem Biol 44 16-22 (2018)
  67. Techniques for molecular imaging probe design. Reynolds F, Kelly KA. Mol Imaging 10 407-419 (2011)
  68. New perspectives on the design of cytokines and growth factors. Kallen KJ, Grötzinger J, Rose-John S. Trends Biotechnol 18 455-461 (2000)
  69. Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy. Finke JM, Banks WA. Hum Antibodies 25 131-146 (2017)
  70. Small and Simple, yet Sturdy: Conformationally Constrained Peptides with Remarkable Properties. Bozovičar K, Bratkovič T. Int J Mol Sci 22 1611 (2021)
  71. Structurally adaptive hot spots at a protein interaction interface on TRAF3. Ely KR, Li C. J Mol Recognit 15 286-290 (2002)
  72. Antibody recruiting molecules (ARMs): synthetic immunotherapeutics to fight cancer. Achilli S, Berthet N, Renaudet O. RSC Chem Biol 2 713-724 (2021)
  73. Nonimmune antibody interactions of Group A Streptococcus M and M-like proteins. Mills JO, Ghosh P. PLoS Pathog 17 e1009248 (2021)
  74. Moonlighting enzymes: when cellular context defines specificity. Gupta MN, Uversky VN. Cell Mol Life Sci 80 130 (2023)
  75. Protein-Protein Interactions in Translesion Synthesis. Dash RC, Hadden K. Molecules 26 5544 (2021)
  76. Circulating non-immune IgG complexes in health and disease. Nezlin R. Immunol Lett 122 141-144 (2009)
  77. PDZ domains and their ligands. Kay BK, Kehoe JW. Chem Biol 11 423-425 (2004)
  78. [Therapeutic agents targetting protein-protein interactions: myth or reality?]. Laudet B, Prudent R, Filhol O, Cochet C. Med Sci (Paris) 23 273-278 (2007)
  79. IgG Fc Affinity Ligands and Their Applications in Antibody-Involved Drug Delivery: A Brief Review. Yang C, He B, Zhang H, Wang X, Zhang Q, Dai W. Pharmaceutics 15 187 (2023)
  80. Peptide Affinity Chromatography Applied to Therapeutic Antibodies Purification. Barredo-Vacchelli GR, Giudicessi SL, Martínez-Ceron MC, Cascone O, Camperi SA. Int J Pept Res Ther 27 2905-2921 (2021)
  81. Peptidomimetics in cancer chemotherapy. Avendaño C, Menéndez JC. Clin Transl Oncol 9 563-570 (2007)
  82. Overcoming phenotypic switching: targeting protein-protein interactions in cancer. Ladias C, Papakotoulas P, Papaioannou M, Papanikolaou NA. Explor Target Antitumor Ther 4 1071-1081 (2023)
  83. Recent Developments and Future Perspectives of Purine Derivatives as a Promising Scaffold in Drug Discovery. Rana N, Grover P, Singh H. Curr Top Med Chem 24 541-579 (2024)
  84. Structural Basis of a Conventional Recognition Mode of IGHV1-69 Rheumatoid Factors. Shiroishi M. Adv Exp Med Biol 21 171-182 (2021)

Articles citing this publication (271)



Quick links